Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry

The authors sought to retrospectively analyze the real‐world evidence on aliskiren in diabetic patients with or without concomitant renin‐angiotensin system (RAS) blocker use based on the Registry for Ambulant Therapy With RAS Inhibitors in Hypertension Patients in Germany (3A). Of 14,986 patients i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Hypertens (Greenwich)
Hlavní autoři: Kistner, Iris, Zeymer, Uwe, Dechend, Ralf, Hagedorn, Ina, Riemer, Thomas, Bramlage, Peter, Pittrow, David, Senges, Jochen, Schmieder, Roland E.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8031948/
https://ncbi.nlm.nih.gov/pubmed/27094460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12828
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky